World Health Organization. Policy Recommendations on Smoking Cessation and Treatment of Tobacco Dependence. WHO, 2003.
de Leon, J, Diaz, FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res
2005; 76: 135–57.
Olincy, A, Young, DA, Freedman, R. Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry
1997; 42: 1–5.
Kelly, C, McCreadie, RG. Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland. Am J Psychiatry
1999; 156: 1751–7.
Williams, JM, Ziedonis, DM, Abanyie, F, Steinberg, ML, Foulds, J, Benowitz, NL. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Schizophr Res
2005; 79: 323–35.
Adler, LE, Hoffer, LD, Wiser, A, Freedman, R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am J Psychiatry
1993; 150: 1856–61.
Sacco, KA, Bannon, KL, George, TP. Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. J Psychopharmacol
2004; 18: 457–74.
Addington, J, el-Guebaly, N, Addington, D, Hodgins, D. Readiness to stop smoking in schizophrenia. Can J Psychiatry
1997; 42: 49–52.
Hughes, JR, Stead, LF, Lancaster, T. Antidepressants for smoking cessation. Cochrane Database Syst Rev
2007; 1: CD000031.
Stahl, SM, Pradko, JF, Haight, BR, Modell, JG, Rockett, CB, Learned-Coughlin, S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry
2004; 6: 159–66.
Fryer, JD, Lukas, RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther
1999; 288: 88–92.
Cryan, JF, Bruijnzeel, AW, Skjei, KL, Markou, A. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl)
2003; 168: 347–58.
Strasser, K. Smoking Reduction and Cessation for People with Schizophrenia: Guidelines for General Practitioners.
SANE Australia & Department of Psychiatry, University of Melbourne, 2001.
World Health Organization. The ICD–10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM–IV). APA, 1994.
Dixon, L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res
1999; 35: S93–100.
West, R, Hajek, P, Stead, L, Stapleton, J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction
2005; 100: 299–303.
Fiore, M, Jaén, C, Baker, T, Bailey, W, Benowitz, NL, Curry, S, et al. Treating Tobacco Use and Dependence: 2008 Update – Clinical Practice Guideline. United States Department of Health and Human Services, 2008.
Higgins, JP, Thompson, SG, Deeks, JJ, Altman, DG. Measuring inconsistency in meta-analyses. BMJ
2003; 327: 557–60.
Fatemi, S, Stary, J, Hatsukami, D, Murphy, S. A double-blind placebo-controlled cross over trial of bupropion in smoking reduction in schizophrenia. Schizophr Res
2005; 76: 353–6.
George, TP, Hitsman, B, Papandonatos, GD, Sacco, KA, Vessicchio, JC, Dudas, M, et al. Predictors of smoking cessation in schizophrenia: analysis of data from three sequential controlled clinical trials. Neuropsychopharmacol
2004; 29 (suppl 1): s103.
Evins, A, Cather, C, Culhane, MA, Birnbaum, A, Horowitz, J, Hsieh, E, et al. A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol
2007; 27: 380–6.
George, TP, Vessicchio, JC, Sacco, KA, Weinberger, AH, Dudas, MM, Allen, TM, et al. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry
2008; 63: 1092–6.
Evins, AE, Cather, C, Culhane, M, Birnbaum, AS, Horowitz, J, Hsieh, E, et al. A placebo-controlled study of bupropion SR added to high dose nicotine replacement therapy for smoking cessation or reduction in schizophrenia
Nicotine Tob Res
2007; 9 (suppl 2): s101.
George, TP, Vessicchio, JC, Weinberger, AH, Sacco, KA. Sustained-release bupropion combined with transdermal nicotine patch for smoking cessation in schizophrenia. Society for Research on Nicotine and Tobacco 13th Annual Meeting.
Society for Research on Nicotine and Tobacco, 2007 (http://www.srnt.org/meeting/2007/pdf/onsite/2007SRNTAbstracts-FINAL.pdf).
Sacco, KA, Hitsman, B, Papandonatos, GD, Vessicchio, JC, Dudas, MM, Termine, A, et al. Predictors of smoking cessation in schizophrenia: analysis of data from three sequential controlled clinical trials. Society for Research on Nicotine and Tobacco 10th Annual Meeting
Society for Research on Nicotine and Tobacco, 2004 (http://184.108.40.206/srnt/abstract/2004/a/retrieveresponse.lasso).
George, TP, Vessicchio, J, Allen, T, Weinberger, A, Sacco, KA. A randomized, double-blind, placebo-controlled trial of sustained-release bupropion combined with transdermal nicotine patch for smoking cessation in schizophrenia: neuropsychological predictors of treatment outcome. Neuropsychopharmacol
2006; 31 (suppl 1): s254–5.
Evins, A, Cather, C, Deckersbach, T, Freudenreich, O, Culhane, MA, Olm-Shipman, CM, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol
2005; 25: 218–25.
Evins, A, Deckersbach, T, Cather, C, Freudenreich, O, Culhane, MA, Henderson, DC, et al. Independent effects of tobacco abstinence and bupropion on cognitive function in schizophrenia. J Clin Psychiatry
2005; 66: 1184–90.
Evins, AE, Cather, C, Culhane, M, Freudenreich, O, Rigotti, NA, Goff, DC. Smoking cessation in schizophrenia: a double blind placebo controlled trial of bupropion SR added to cognitive behavioral therapy. Biological Psychiatry
2004; 55: 226S.
Evins, AE, Cather, C, Goff, DC, Olm-Shipman, C, Rigotti, NA. A placebo controlled trial of bupropion SR for smoking cessation in schizophrenia. Society for Research on Nicotine and Tobacco 9th Annual Meeting. Society for Research on Nicotine and Tobacco, 2003 (http://220.127.116.11/srnt/abstract/r/retrieveresponse.lasso?-MaxRecords=1&-SortField=Abstract_Title&-SortOrder=ascending&-Op=cn&Abstract_Title=&-Op=cn&Abstract=&-Op=cn&Authors=evins&-SkipRecords=0).
Evins, A, Mays, VK, Rigotti, NA, Tisdale, T, Cather, C, Goff, DC. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res
2001; 3: 397–403.
George, TP, Vessicchio, JC, Termine, A, Bregartner, TA, Feingold, A, Rounsaville, BJ, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry
2002; 52: 53–61.
Evins, A, Cather, C, Goff, DC, Rigotti, NA. Increased smoking cessation and reduction: two years following a smoking cessation trial in patients with schizophrenia. Society for Research on Nicotine and Tobacco 9th Annual Meeting. Society for Research on Nicotine and Tobacco, 2003 (http://18.104.22.168/srnt/abstract/a/retrieveresponse.lasso).
Vessicchio, JC, Termine, A, Bregartner, TA, George, TP. Bupropion versus placebo for smoking cessation in schizophrenia. Drug Alcohol Depend
2002; 66: s187.
Evins, AE, Cather, C, Rigotti, NA, Freudenreich, O, Henderson, DC, Olm-Shipman, CM, et al. Two-year follow-up of a smoking cessation trial in patients with schizophrenia: increased rates of smoking cessation and reduction. J Clin Psychiatry
2004; 65: 307–11.
Weiner, E, Buchanan, R, Gold, J, Ball, P, Bennett, M. A comparison of bupropion SR and placebo for smoking cessation in schizophrenia. Schizophr Res
2003; 60: 305–6.
Weiner, E, Ball, MP, Buchanan, R, Gold, JM. A comparison of bupropion SR and placebo for smoking cessation. Schizophr Bull
2007; 33: 465.
Eliasson, B, Hjalmarson, A, Kruse, E, Landfeldt, B, Westin, A. Effect of smoking reduction and cessation on cardiovascular risk factors. Nicotine Tob Res
2001; 3: 249–55.
Hatsukami, DK, Kotlyar, M, Allen, S, Jensen, J, Li, S, Le, C, et al. Effects of cigarette reduction on cardiovascular risk factors and subjective measures. Chest
2005; 128: 2528–37.
Hennekens, CH, Hennekens, AR, Hollar, D, Casey, DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J
2005; 150: 1115–21.
Osby, U, Correia, N, Brandt, L, Ekbom, A, Sparen, P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res
2000; 45: 21–8.
Daumit, GL, Goldberg, RW, Anthony, C, Dickerson, F, Brown, CH, Kreyenbuhl, J, et al. Physical activity patterns in adults with severe mental illness. J Nerv Ment Dis
2005; 193: 641–6.
Strassnig, M, Brar, JS, Ganguli, R. Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr Bull
2003; 29: 393–7.
McCreadie, RG. Diet, smoking and cardiovascular risk in people with schizophrenia. Descriptive study. Br J Psychiatry
2003; 183: 534–9.
Newcomer, JW, Haupt, DW. The metabolic effects of antipsychotic medications. Can J Psychiatry
2006; 51: 480–91.
Meyer, JM, Koro, CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res
2004; 70: 1–17.
Marder, SR, Essock, SM, Miller, AL, Buchanan, RW, Casey, DE, Davis, JM, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry
2004; 161: 1334–49.
Brown, S, Inskip, H, Barraclough, B. Causes of the excess mortality of schizophrenia. Br J Psychiatry
2000; 177: 212–7.
Lichtermann, D, Ekelund, J, Pukkala, E, Tanskanen, A, Lonnqvist, J. Incidence of cancer among persons with schizophrenia and their relatives. Arch Gen Psychiatry
2001; 58: 573–8.
Zwar, N, Richmond, R, Borland, R, Peters, M, Stilman, S, Litt, J, et al. Smoking cessation Pharmacotherapy: An Update for Health Professionals. Royal Australian College of General Practitioners, 2007.
Department of Health. Choosing Health: Making Healthier Choices Easier.
Department of Health, 2004.
David, SP, Brown, RA, Papandonatos, GD, Kahler, CW, Lloyd-Richardson, EE, Munafo, MR, et al. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob Res
2007; 9: 821–33.
Lerman, C, Jepson, C, Wileyto, EP, Epstein, LH, Rukstalis, M, Patterson, F, et al. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology
2006; 31: 231–42.
Shearer, J, Shanahan, M. Cost effectiveness analysis of smoking cessation interventions. Aust N Z J Public Health
2006; 30: 428–34.
Cornuz, J, Pinget, C, Gilbert, A, Paccaud, F. Cost-effectiveness analysis of the first-line therapies for nicotine dependence. Eur J Clin Pharmacol
2003; 59: 201–6.
Bertram, MY, Lim, SS, Wallace, AL, Vos, T. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia. Tob Control
2007; 16: 255–60.